Myeloproliferative Leukemia Mutation Screening MPL – S505N; W515L Test
Test Name: Myeloproliferative Leukemia Mutation Screening MPL – S505N; W515L Test
Components: EDTA Vacutainer (2ml)
Price: 1350.0 AED
Sample Condition: Bone Marrow/Peripheral Blood
Report Delivery: 5-7 days
Method: Sanger Sequencing
Test Type: Genetics
Doctor: Gynecologist
Test Department:
Pre Test Information: Myeloproliferative Leukemia Mutation Screening (MPL – S505N; W515L) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
The MPL – S505N and W515L mutations are specific genetic alterations that can occur in myeloproliferative leukemia (MPL). MPL is a type of leukemia characterized by the excessive production of myeloid cells in the bone marrow. It is often associated with mutations in genes such as JAK2, CALR, and MPL.
The MPL – S505N mutation refers to a change in the DNA sequence at position 505 of the MPL gene. This mutation has been found to be associated with myeloproliferative disorders, including essential thrombocythemia and primary myelofibrosis. The S505N mutation leads to increased activation of the MPL receptor, resulting in abnormal signaling and excessive production of blood cells.
The W515L mutation, on the other hand, refers to a change in the DNA sequence at position 515 of the MPL gene. This mutation is also associated with myeloproliferative disorders, particularly primary myelofibrosis. The W515L mutation leads to constitutive activation of the MPL receptor, causing abnormal signaling and uncontrolled cell growth.
Mutation screening for MPL – S505N and W515L is performed using molecular genetic testing techniques. This involves analyzing the DNA sequence of the MPL gene to identify any mutations present. This screening is important for the diagnosis and management of myeloproliferative leukemia, as it helps to determine the specific genetic alterations that are driving the disease. It can also guide treatment decisions, as certain targeted therapies may be more effective against specific mutations.
Overall, MPL – S505N and W515L mutation screening plays a crucial role in the molecular diagnosis and management of myeloproliferative leukemia.
| Test Name | Myeloproliferative Leukemia Mutation Screening MPL – S505N; W515L Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 1350.0 AED |
| Sample Condition | Bone Marrow\/Peripheral Blood |
| Report Delivery | 5-7 days |
| Method | Sanger Sequencing |
| Test type | Genetics |
| Doctor | Gynecologist |
| Test Department: | |
| Pre Test Information | Myeloproliferative Leukemia Mutation Screening (MPL – S505N; W515L) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
The MPL – S505N and W515L mutations are specific genetic alterations that can occur in myeloproliferative leukemia (MPL). MPL is a type of leukemia characterized by the excessive production of myeloid cells in the bone marrow. It is often associated with mutations in genes such as JAK2, CALR, and MPL. The MPL – S505N mutation refers to a change in the DNA sequence at position 505 of the MPL gene. This mutation has been found to be associated with myeloproliferative disorders, including essential thrombocythemia and primary myelofibrosis. The S505N mutation leads to increased activation of the MPL receptor, resulting in abnormal signaling and excessive production of blood cells. The W515L mutation, on the other hand, refers to a change in the DNA sequence at position 515 of the MPL gene. This mutation is also associated with myeloproliferative disorders, particularly primary myelofibrosis. The W515L mutation leads to constitutive activation of the MPL receptor, causing abnormal signaling and uncontrolled cell growth. Mutation screening for MPL – S505N and W515L is performed using molecular genetic testing techniques. This involves analyzing the DNA sequence of the MPL gene to identify any mutations present. This screening is important for the diagnosis and management of myeloproliferative leukemia, as it helps to determine the specific genetic alterations that are driving the disease. It can also guide treatment decisions, as certain targeted therapies may be more effective against specific mutations. Overall, MPL – S505N and W515L mutation screening plays a crucial role in the molecular diagnosis and management of myeloproliferative leukemia. |
